AVITA Medical (RCEL) investor relations material

Introduction and agenda

• Interim analysis from the Cohealyx-I study was reviewed, focusing on time to autografting versus literature benchmarks.

• Covered introduction, Cohealyx in acute wound care, KOL discussion, closing remarks, and Q&A.

• Presenters included key surgeons, company leadership, and scientific affairs, with a Q&A session following the main discussion.

KOL background and credentials

• Dr. Derek Bell is Professor of Surgery and Burn Director at the University of Rochester Medical Center.

• Dr. Lourdes Castañón is Clinical Associate Professor of Surgery and Burn Program Director at Banner – University Medical Center Tucson.

• Panel included interim CEO, SVP of Scientific and Medical Affairs, and burn/plastic surgery experts from University of Rochester and University of Arizona.

Market insights and analysis

• Acute wound care is resource-intensive and procedure-driven, with repeat product use by specialized hospital teams, increasing value per case.

• Growth is driven by increased utilization within existing accounts, not by adding new accounts.

• Portfolio includes RECELL, Cohealyx, and PermeaDerm, each targeting different wound healing stages.

• Over one-third of patients in prior trials received a dermal matrix, highlighting the need for improved solutions.

• Technologies aim to accelerate recovery, improve efficiency, and reduce care burden.